Here are the staff publications for December 2021 & January 2022.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 2nd February 2022.

 

1. Abo YN, Curtis N, Osowicki J, Haeusler G, Purcell R, Kadambari S, De Wachter M, Vanden Driessche K, Dekeyzer S, Coleman L, Crawford N, Graham S, Marais B, Gwee A. Infliximab for Paradoxical Reactions in Pediatric Central Nervous System Tuberculosis. J Pediatric Infect Dis Soc 2021;10:1087-91.

2. Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 2022;18:425-36.

3. Aide N, Iravani A, Prigent K, Kottler D, Alipour R, Hicks RJ. PET/CT variants and pitfalls in malignant melanoma. Cancer Imaging 2022;22:3.

4. Anton A, Tran B. Global Disparity in Access to Novel Therapeutics for Metastatic Prostate Cancer. JCO Oncol Pract 2022;18:57-9.

5. Archer C, Veall J, Duggan LV, Downey A, Rose P. A comparison of patient and provider perceptions of awake tracheal intubations. Can J Anaesth 2022;69:179-81.

6. Azodi CB, Zappia L, Oshlack A, McCarthy DJ. splatPop: simulating population scale single-cell RNA sequencing data. Genome Biol 2021;22:341.

7. Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady AF, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Christensen LL, Cini G, Claes KBM, Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Ding YC, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Evans DG, Feliubadaló L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J, Izatt L, Izquierdo A, James PA, Janavicius R, Jensen UB, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernández A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, Muranen TA, Murray A, Nathanson KL, Neuhausen SL, Nevanlinna H, Nguyen-Dumont T, Niederacher D, Olah E, Olopade OI, Palli D, Parsons MT, Pedersen IS, Peissel B, Perez-Segura P, Peterlongo P, Petersen AH, Pinto P, Porteous ME, Pottinger C, Pujana MA, Radice P, Ramser J, Rantala J, Robson M, Rogers MT, Rønlund K, Rump A, Sánchez de Abajo AM, Shah PD, Sharif S, Side LE, Singer CF, Stadler Z, Steele L, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teulé A, Thull DL, Tischkowitz M, Toland AE, Tommasi S, Toss A, Trainer AH, Tripathi V, Valentini V, van Asperen CJ, Venturelli M, Viel A, Vijai J, Walker L, Wang-Gohrke S, Wappenschmidt B, Whaite A, Zanna I, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst 2022;114:109-22.

8. Body A, Wong R, Shapiro J, Jalali A, McLachlan SA, Ananda S, Lipton L, Cooray P, Gibbs P, Lee B, Lee M. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. Intern Med J 2022;52:49-56.

9. Bournazos AM, Riley LG, Bommireddipalli S, Ades L, Akesson LS, Al-Shinnag M, Alexander SI, Archibald AD, Balasubramaniam S, Berman Y, Beshay V, Boggs K, Bojadzieva J, Brown NJ, Bryen SJ, Buckley MF, Chong B, Davis MR, Dawes R, Delatycki M, Donaldson L, Downie L, Edwards C, Edwards M, Engel A, Ewans LJ, Faiz F, Fennell A, Field M, Freckmann ML, Gallacher L, Gear R, Goel H, Goh S, Goodwin L, Hanna B, Harraway J, Higgins M, Ho G, Hopper BK, Horton AE, Hunter MF, Huq AJ, Josephi-Taylor S, Joshi H, Kirk E, Krzesinski E, Kumar KR, Lemckert F, Leventer RJ, Lindsey-Temple SE, Lunke S, Ma A, Macaskill S, Mallawaarachchi A, Marty M, Marum JE, McCarthy HJ, Menezes MP, McLean A, Milnes D, Mohammad S, Mowat D, Niaz A, Palmer EE, Patel C, Patel SG, Phelan D, Pinner JR, Rajagopalan S, Regan M, Rodgers J, Rodrigues M, Roxburgh RH, Sachdev R, Roscioli T, Samarasekera R, Sandaradura SA, Savva E, Schindler T, Shah M, Sinnerbrink IB, Smith JM, Smith RJ, Springer A, Stark Z, Strom SP, Sue CM, Tan K, Tan TY, Tantsis E, Tchan MC, Thompson BA, Trainer AH, van Spaendonck-Zwarts K, Walsh R, Warwick L, White S, White SM, Williams MG, Wilson MJ, Wong WK, Wright DC, Yap P, Yeung A, Young H, Jones KJ, Bennetts B, Cooper ST. Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants. Genet Med 2022;24:130-45.

10. Brodsky RA, Lee JW, Nishimura JI, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? Br J Haematol 2022;196:264-5.

11. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol 2022;40:52-62.

12. Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V. Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1:Cd013453.

13. Carmichael L, Rocca R, Laing E, Ashford P, Collins J, Jackson L, McPherson L, Pendergast B, Kiss N. Early postoperative feeding following surgery for upper gastrointestinal cancer: A systematic review. J Hum Nutr Diet 2022;35:33-48.

14. Chau TCY, Baek S, Coxam B, Skoczylas R, Rondon-Galeano M, Bower NI, Wainwright EN, Stacker SA, Cooper HM, Koopman PA, Lagendijk AK, Harvey NL, François M, Hogan BM. Pkd1 and Wnt5a genetically interact to control lymphatic vascular morphogenesis in mice. Dev Dyn 2022;251:336-49.

15. Chen K, Murphy D, Lawrentschuk N. Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones. J Urol 2022;207:265-7.

16. Choi PY, Merriman E, Bennett A, Enjeti AK, Tan CW, Goncalves I, Hsu D, Bird R. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Med J Aust 2022;216:43-52.

17. Chong E, Ratnayake B, Dasari BVM, Loveday BPT, Siriwardena AK, Pandanaboyana S. Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta-Analysis. World J Surg 2022;46:223-34.

18. Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 2021;7:91.

19. Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O'Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. Int J Cancer 2022;150:993-1006.

20. Crowe J, Francis JJ, Edbrooke L, Loeliger J, Joyce T, Prickett C, Martin A, Khot A, Denehy L. Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre. Support Care Cancer 2022;30:1841-52.

21. Davidson NM, Chen Y, Sadras T, Ryland GL, Blombery P, Ekert PG, Göke J, Oshlack A. JAFFAL: detecting fusion genes with long-read transcriptome sequencing. Genome Biol 2022;23:10.

22. Deftereos I, Yeung JM, Arslan J, Carter VM, Isenring E, Kiss N. Adherence to ESPEN guidelines and associations with postoperative outcomes in upper gastrointestinal cancer resection: results from the multi-centre NOURISH point prevalence study. Clin Nutr ESPEN 2022;47:391-8.

23. Degeling K, MJ IJ, Groothuis-Oudshoorn CGM, Franken MD, Koopman M, Clements MS, Koffijberg H. Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. Value Health 2022;25:104-15.

24. Delahunt B, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Kenwright DN, Matthews J, Murray JD, Oldmeadow C, Samaratunga H, Spry NA, Thunders MC, Hondermarck H, Denham JW. Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. Pathology 2022;54:49-54.

25. Delany C, Milch V, Keefe D, Wong ZW. COVID-19 recovery: implications for cancer care clinicians. Support Care Cancer 2022;30:1003-6.

26. Dervisevic E, Voelcker NH, Risbridger G, Tuck KL, Cadarso VJ. Colorimetric Detection of Extracellular Hydrogen Peroxide Using an Integrated Microfluidic Device. Anal Chem 2022;94:1726-32.

27. Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer 2022;22:45-64.

28. Edbrooke L, Khaw P, Freimund A, Carpenter D, McNally O, Joubert L, Loeliger J, Traill A, Gough K, Mileshkin L, Denehy L. ENhAncing Lifestyle Behaviors in EndometriaL CancEr (ENABLE): A Pilot Randomized Controlled Trial. Integr Cancer Ther 2022;21:15347354211069885.

29. Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. Lancet Oncol 2022;23:e14-e5.

30. Fennell KA, Vassiliadis D, Lam EYN, Martelotto LG, Balic JJ, Hollizeck S, Weber TS, Semple T, Wang Q, Miles DC, MacPherson L, Chan YC, Guirguis AA, Kats LM, Wong ES, Dawson SJ, Naik SH, Dawson MA. Non-genetic determinants of malignant clonal fitness at single-cell resolution. Nature 2022;601:125-31.

31. Ferguson MT, Kusre S, Myles PS. Minimal clinically important difference in days at home up to 30 days after surgery. Anaesthesia 2022;77:196-200.

32. Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. Genome Med 2021;13:186.

33. Flood M, Narasimhan V, Wilson K, Lim WM, Ramsay R, Michael M, Heriot A. ASO Visual Abstract: Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer-A Systematic Review. Ann Surg Oncol 2022;29:62-3.

34. Flood M, Narasimhan V, Wilson K, Lim WM, Ramsay R, Michael M, Heriot A. Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review. Ann Surg Oncol 2022;29:47-59.

35. Flood M, Ramsay R, Heriot A. ASO Author Reflections: Organoid-Based Precision Medicine in Colorectal Cancer-Are We There Yet? Ann Surg Oncol 2022;29:60-1.

36. Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M. Tumor Sink Effect in (68)Ga-PSMA-11 PET: Myth or Reality? J Nucl Med 2022;63:226-32.

37. Gates P, Dhillon H, Gough K, Wilson C, Hawkes E, Scudder L, Cushion T, Krishnasamy M. Correction to: Exploration of motivation to participate in a study of cancer-related cognitive impairment among patients with newly diagnosed aggressive lymphoma: a qualitative sub-study. Support Care Cancer 2022;30:1341-2.

38. Gates P, Dhillon H, Gough K, Wilson C, Hawkes E, Scudder L, Cushion T, Krishnasamy M. Exploration of motivation to participate in a study of cancer-related cognitive impairment among patients with newly diagnosed aggressive lymphoma: a qualitative sub-study. Support Care Cancer 2022;30:1331-9.

39. Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer 2021;162:22-33.

40. Granger CL, Edbrooke L, Antippa P, Wright G, McDonald CF, Lamb KE, Irving L, Krishnasamy M, Abo S, Whish-Wilson GA, Truong D, Denehy L, Parry SM. Effect of a postoperative home-based exercise and self-management programme on physical function in people with lung cancer (CAPACITY): protocol for a randomised controlled trial. BMJ Open Respir Res 2022;9.

41. Green TE, MacGregor D, Carden SM, Harris RV, Hewitt CA, Berkovic SF, Penington AJ, Scheffer IE, Hildebrand MS. Identification of a recurrent mosaic KRAS variant in brain tissue from an individual with nevus sebaceous syndrome. Cold Spring Harb Mol Case Stud 2021;7.

42. Guccione L, Gough K, Drosdowsky A, Price T, Pavlakis N, Wyld D, Ransom D, Michael M, Schofield P. The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. Patient Educ Couns 2022;105:212-20.

43. Harun A, Kan A, Schwabenbauer K, Gilgado F, Perdomo H, Firacative C, Losert H, Abdullah S, Giraud S, Kaltseis J, Fraser M, Buzina W, Lackner M, Blyth CC, Arthur I, Rainer J, Lira JFC, Artigas JG, Tintelnot K, Slavin MA, Heath CH, Bouchara JP, Chen SCA, Meyer W. Multilocus Sequence Typing Reveals Extensive Genetic Diversity of the Emerging Fungal Pathogen Scedosporium aurantiacum. Front Cell Infect Microbiol 2021;11:761596.

44. Harvey M, Chislett B, Perera M, Lawrentschuk N, Bolton D, Jack G. Critical shortage in BCG immunotherapy: How did we get here and where will it take us? Urol Oncol 2022;40:1-3.

45. Hicks R, Czernin J, Herrmann K. Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann. J Nucl Med 2022;63:1-4.

46. Hodel AW, Rudd-Schmidt JA, Trapani JA, Voskoboinik I, Hoogenboom BW. Lipid specificity of the immune effector perforin. Faraday Discuss 2021;232:236-55.

47. Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv 2021;5:5098-106.

48. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med 2022;63:59-68.

49. John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol 2022;76:102080.

50. Kehm RD, MacInnis RJ, John EM, Liao Y, Kurian AW, Genkinger JM, Knight JA, Colonna SV, Chung WK, Milne R, Zeinomar N, Dite GS, Southey MC, Giles GG, McLachlan SA, Whitaker KD, Friedlander ML, Weideman PC, Glendon G, Nesci S, Phillips KA, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB. Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectr 2021;5:pkab090.

51. Kok PS, Lee K, Lord S, John T, Marschner I, Wu YL, Mok TSK, Lee CK. Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. Lung Cancer 2022;163:14-8.

52. Kubinyecz O, Santos F, Drage D, Reik W, Eckersley-Maslin MA. Maternal Dppa2 and Dppa4 are dispensable for zygotic genome activation but important for offspring survival. Development 2021;148.

53. Kusnadi EP, Timpone C, Topisirovic I, Larsson O, Furic L. Regulation of gene expression via translational buffering. Biochim Biophys Acta Mol Cell Res 2022;1869:119140.

54. Lau PKH, Cullinane C, Jackson S, Walker R, Smith LK, Slater A, Kirby L, Patel RP, von Scheidt B, Slaney CY, McArthur GA, Sheppard KE. Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma. Cancers (Basel) 2021;13.

55. Li H, Engel C, de la Hoya M, Peterlongo P, Yannoukakos D, Livraghi L, Radice P, Thomassen M, Hansen TVO, Gerdes AM, Nielsen HR, Caputo SM, Zambelli A, Borg A, Solano A, Thomas A, Parsons MT, Antoniou AC, Leslie G, Yang X, Chenevix-Trench G, Caldes T, Kwong A, Pedersen IS, Lautrup CK, John EM, Terry MB, Hopper JL, Southey MC, Andrulis IL, Tischkowitz M, Janavicius R, Boonen SE, Kroeldrup L, Varesco L, Hamann U, Vega A, Palmero EI, Garber J, Montagna M, Van Asperen CJ, Foretova L, Greene MH, Selkirk T, Moller P, Toland AE, Domchek SM, James PA, Thorne H, Eccles DM, Nielsen SM, Manoukian S, Pasini B, Caligo MA, Lazaro C, Kirk J, Wappenschmidt B, Spurdle AB, Couch FJ, Schmutzler R, Goldgar DE. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genet Med 2022;24:119-29.

56. Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. Br J Cancer 2022;126:310.

57. Lim BWX, Li N, Rowley SM, Thompson ER, McInerny S, Zethoven M, Scott RJ, Devereux L, Sloan EK, James PA, Campbell IG. Integration of tumour sequencing and case-control data to assess pathogenicity of RAD51C missense variants in familial breast cancer. NPJ Breast Cancer 2022;8:10.

58. Lin T, Pham J, Paul E, Conron M, Wright G, Ball D, Mitchell P, Atkin N, Brand M, Zalcberg J, Stirling RG. Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study. Lung Cancer 2022;163:69-76.

59. Lippey J, Keogh L, Campbell I, Mann GB, Forrest L. Development and pilot testing of an online decision aid for women considering risk-stratified breast screening. J Community Genet 2022;13:137-41.

60. Liu Z, Martin JH, Liauw W, McLachlan SA, Link E, Matera A, Thompson M, Jefford M, Hicks RJ, Cullinane C, Hatzimihalis A, Campbell I, Crowley S, Beale PJ, Karapetis CS, Price T, Burge ME, Michael M. Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. Eur J Clin Pharmacol 2022;78:53-64.

61. Livingston PM, Russell L, Orellana L, Winter N, Jefford M, Girgis A, Austin D, O E, Mihalopoulos C, Ugalde A, Chambers R, Phipps-Nelson J, Herath D, Botti M, Rasmussen B, Whitfield K, Ftanou M, Smith AB, Pilatti K, Sara S, Wootten A, Gillan K, Singh M, Campbell D, Pillay B, White V. Efficacy and cost-effectiveness of an online mindfulness program (MindOnLine) to reduce fear of recurrence among people with cancer: study protocol for a randomised controlled trial. BMJ Open 2022;12:e057212.

62. Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer 2022;8:3.

63. Lucas CG, Gupta R, Wu J, Shah K, Ravindranathan A, Barreto J, Gener M, Ginn KF, Prall OWJ, Xu H, Kee D, Ko HS, Yaqoob N, Zia N, Florez A, Cha S, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathol 2022;143:109-13.

64. Masle-Farquhar E, Peters TJ, Miosge LA, Parish IA, Weigel C, Oakes CC, Reed JH, Goodnow CC. Uncontrolled CD21(low) age-associated and B1 B cell accumulation caused by failure of an EGR2/3 tolerance checkpoint. Cell Rep 2022;38:110259.

65. Mato AR, Sharman JP, Biondo JML, Wu M, Mun Y, Kim SY, Humphrey K, Boyer M, Zhu Q, Seymour JF. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study. Haematologica 2022;107:134-42.

66. McDowell L, Magarey MJR, Rischin D. Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer. J Clin Oncol 2022;40:114-7.

67. McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R. Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leuk Lymphoma 2021:1-8.

68. Meiser B, Monnik M, Austin R, Nichols C, Cops E, Salmon L, Spurdle AB, Macrae F, Taylor N, Pachter N, James P, Kaur R. Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study. J Community Genet 2022;13:59-73.

69. Miller JH, Gilbertson M, MacManus MP, Wirth A, Opat SS, Gregory GP. Salvage radiotherapy is associated with durable response for a subset of patients with limited-stage refractory DLBCL. Blood Adv 2021;5:5112-5.

70. Mills G, Anderson MA, Tang C, Hamad N. The untold effect of the combined oral contraceptive pill on anticancer drugs. Lancet Haematol 2022;9:e10-e1.

71. Minson A, Hofman M, Dickinson M. A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse. Leuk Lymphoma 2022;63:1-4.

72. Muraro E, De Zorzi M, Miolo G, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Dolcetti R, Steffan A, De Re V. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Front Immunol 2021;12:791958.

73. Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2022;22:39-51.

74. Nguyen TK, Chin L, Sahgal A, Dagan R, Eppinga W, Guckenberger M, Kim JH, Lo SS, Redmond KJ, Siva S, Stish BJ, Chan R, Lawrence L, Lau A, Tseng CL. International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. Int J Radiat Oncol Biol Phys 2022;112:351-60.

75. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH, Jr., Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol 2022:Jco2101874.

76. Patten RK, Pascoe MC, Moreno-Asso A, Boyle RA, Stepto NK, Parker AG. Effectiveness of exercise interventions on mental health and health-related quality of life in women with polycystic ovary syndrome: a systematic review. BMC Public Health 2021;21:2310.

77. Piotin A, Godet J, Trubiano JA, Grandbastien M, Guénard-Bilbault L, de Blay F, Metz-Favre C. Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Ann Allergy Asthma Immunol 2022;128:27-32.

78. Pitiyarachchi O, Phillips KA, Friedlander M. Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation. Cancer Treat Res Commun 2022;30:100504.

79. Qin VM, Haynes NM, D'Souza C, Neeson PJ, Zhu JJ. CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors. Front Immunol 2021;12:813832.

80. Rambhatla JS, Tonkin-Hill GQ, Takashima E, Tsuboi T, Noviyanti R, Trianty L, Sebayang BF, Lampah DA, Marfurt J, Price RN, Anstey NM, Papenfuss AT, Damelang T, Chung AW, Duffy MF, Rogerson SJ. Identifying targets of protective antibodies against severe malaria in Papua, Indonesia using locally expressed domains of Plasmodium falciparum Erythrocyte Membrane Protein 1. Infect Immun 2021:Iai0043521.

81. Reifels L, Krishnamoorthy S, Kõlves K, Francis J. Implementation Science in Suicide Prevention. Crisis 2022;43:1-7.

82. Rischin KJ, Mostaghim M, Rao A, Smith B, O'Brien TA, Trubiano JA, Frith K, McMullan B. ESCAPE-Allergy: Evaluating screening for children and adolescents with penicillin allergy. J Paediatr Child Health 2022;58:83-9.

83. Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, Cope W, Dariush A, Dawson SJ, Abraham JE, Dunn J, Hiller L, Thomas J, Cameron DA, Bartlett JMS, Hayward L, Pharoah PD, Markowetz F, Rueda OM, Earl HM, Caldas C. Multi-omic machine learning predictor of breast cancer therapy response. Nature 2022;601:623-9.

84. Schmidt B, Cmero M, Ekert P, Davidson N, Oshlack A. Slinker: Visualising novel splicing events in RNA-Seq data. F1000Res 2021;10:1255.

85. Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology 2022;54:6-19.

86. Sek K, Chan CW, Beavis PA, Darcy PK. Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells. Cancer Cell 2021;39:1564-6.

87. Seth N, Seth I, Bulloch G, Siu AHY, Guo A, Chatterjee R, MacManus M, Donnan L. (18) F-FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta-analysis. Pediatr Blood Cancer 2022;69:e29415.

88. Seymour JF. CLL12: a positive answer to a poorly phrased question. Blood 2022;139:151-2.

89. Shanthikumar S, Neeland MR, Saffery R, Ranganathan SC, Oshlack A, Maksimovic J. DNA Methylation Profiles of Purified Cell Types in Bronchoalveolar Lavage: Applications for Mixed Cell Paediatric Pulmonary Studies. Front Immunol 2021;12:788705.

90. Slavin MA, Chen YC, Cordonnier C, Cornely OA, Cuenca-Estrella M, Donnelly JP, Groll AH, Lortholary O, Marty FM, Nucci M, Rex JH, Rijnders BJA, Thompson GR, Verweij PE, White PL, Hargreaves R, Harvey E, Maertens JA. When to change treatment of acute invasive aspergillosis: an expert viewpoint. J Antimicrob Chemother 2021;77:16-23.

91. Song AJ, Ding K, Alnahhas I, Laperriere NJ, Perry J, Mason WP, Winch C, O'Callaghan CJ, Menten JJ, Brandes AA, Phillips C, Fay MF, Nishikawa R, Osoba D, Cairncross JG, Roa W, Wick W, Shi W. Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial. Neurooncol Adv 2022;4:vdac011.

92. Southey MC, Dowty JG, Riaz M, Steen JA, Renault AL, Tucker K, Kirk J, James P, Winship I, Pachter N, Poplawski N, Grist S, Park DJ, Pope BJ, Mahmood K, Hammet F, Mahmoodi M, Tsimiklis H, Theys D, Rewse A, Willis A, Morrow A, Speechly C, Harris R, Sebra R, Schadt E, Lacaze P, McNeil JJ, Giles GG, Milne RL, Hopper JL, Nguyen-Dumont T. Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing. NPJ Breast Cancer 2021;7:153.

93. Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ. Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. J Clin Oncol 2021:Jco2100941.

94. Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol 2022;196:488-506.

95. Szer J. The Journal in 2021. Intern Med J 2022;52:5-6.

96. Tam CS. Upfront therapy: the case for continuous treatment. Hematology Am Soc Hematol Educ Program 2021;2021:55-8.

97. Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol 2022;23:138-48.

98. Tan DS, Thomas M, Kim DW, Szpakowski S, Urban P, Mehra R, Chow LQM, Sharma S, Solomon BJ, Felip E, Camidge DR, Vansteenkiste J, Petruzzelli L, Pantano S, Shaw AT. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. Lung Cancer 2022;163:7-13.

99. Taylor EV, Lyford M, Parsons L, Holloway M, Gough K, Sabesan S, Thompson SC. Putting Policy into Practice: How Three Cancer Services Perform against Indigenous Health and Cancer Frameworks. Int J Environ Res Public Health 2022;19.

100. Teh BW, Leung VKY, Mordant FL, Sullivan SG, Joyce T, Harrison SJ, Khvorov A, Barr IG, Subbarao K, Slavin MA, Worth LJ. A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation. Clin Infect Dis 2021;73:e4269-e77.

101. Tellambura M, Cumberbatch M, Goad J. A case of acute-colonic pseudo-obstruction (Ogilvie Syndrome) post robot-assisted radical prostatectomy. Urol Case Rep 2022;40:101878.

102. Thompson ER, Nguyen T, Kankanige Y, Markham JF, Anderson MA, Handunnetti SM, Thijssen R, Yeh PS, Tam CS, Seymour JF, Roberts AW, Westerman DA, Blombery P. Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. Blood Adv 2022;6:503-8.

103. Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, August KJ, Myers GD, Tam CS, Jaeger U, Foley SR, Borchmann P, Schuster SJ, Waller EK, Awasthi R, Potthoff B, Warren A, Waldron ER, McBlane F, Chassot-Agostinho A, Laetsch TW. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv 2021;5:4980-91.

104. Tino RB, Yeo AU, Brandt M, Leary M, Kron T. A customizable anthropomorphic phantom for dosimetric verification of 3D-printed lung, tissue, and bone density materials. Med Phys 2022;49:52-69.

105. Tiong IS, Dillon R, Ivey A, Kuzich JA, Thiagarajah N, Sharplin KM, Kok CH, Tedjaseputra A, Rowland JP, Grove CS, Abro E, Shortt J, Hiwase DK, Bajel A, Potter NE, Smith ML, Hemmaway CJ, Thomas A, Gilkes AF, Russell NH, Wei AH. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv 2021;5:5107-11.

106. Toivanen R, Porter LH, Li Z, Clouston D, Risbridger GP, Taylor RA. Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. Cancer Lett 2022;524:182-92.

107. Vasina EN, Greer P, Thwaites D, Kron T, Lehmann J. A system for real-time monitoring of breath-hold via assessment of internal anatomy in tangential breast radiotherapy. J Appl Clin Med Phys 2022;23:e13473.

108. Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nat Rev Cancer 2022;22:5-24.

109. Visan KS, Lobb RJ, Wen SW, Bedo J, Lima LG, Krumeich S, Palma C, Ferguson K, Green B, Niland C, Cloonan N, Simpson PT, McCart Reed AE, Everitt SJ, MacManus MP, Hartel G, Salomon C, Lakhani SR, Fielding D, Möller A. Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients. Cancers (Basel) 2022;14.

110. Wellinger LC, Hogg SJ, Newman DM, Friess T, Geiss D, Michie J, Ramsbottom KM, Bacac M, Fauti T, Marbach D, Jarassier L, Thienger P, Paehler A, Cluse LA, Kearney CJ, Vervoort SJ, Trapani JA, Oliaro J, Shortt J, Ruefli-Brasse A, Rohle D, Johnstone RW. BET Inhibition Enhances TNF-Mediated Antitumor Immunity. Cancer Immunol Res 2022;10:87-107.

111. Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, MJ IJ, Trainer AH. Heterogeneity in how women value risk-stratified breast screening. Genet Med 2022;24:146-56.

112. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol 2022;40:127-37.

113. Wong AKY, Collins A, Ng A, Buizen L, Philip J, Le B. Evaluation of a Large Scale Advance Care Planning Co-Design Education Program for Chinese-Speaking People in Australia. Am J Hosp Palliat Care 2022;39:178-83.

114. Wong SW, Vivash L, Mudududdla R, Nguyen N, Hermans SJ, Shackleford DM, Field J, Xue L, Aprico A, Hancock NC, Haskali M, Stashko MA, Frye SV, Wang X, Binder MD, Ackermann U, Parker MW, Kilpatrick TJ, Baell JB. Development of [(18)F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. Eur J Med Chem 2021;226:113822.

115. Wortman BG, Post CCB, Powell ME, Khaw P, Fyles A, D'Amico R, Haie-Meder C, Jürgenliemk-Schulz IM, McCormack M, Do V, Katsaros D, Bessette P, Baron MH, Nout RA, Whitmarsh K, Mileshkin L, Lutgens L, Kitchener HC, Brooks S, Nijman HW, Astreinidou E, Putter H, Creutzberg CL, de Boer SM. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2022;112:390-9.

116. Zidan L, Iravani A, Oleinikov K, Ben-Haim S, Gross DJ, Meirovitz A, Maimon O, Akhurst T, Michael M, Hicks RJ, Grozinsky-Glasberg S, Kong G. Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study. J Nucl Med 2022;63:218-25.

117. Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Adv 2022;6:590-9.